{"id":10,"date":"2020-12-14T14:51:03","date_gmt":"2020-12-14T12:51:03","guid":{"rendered":"https:\/\/www.oramanetwork.gr\/en\/?page_id=10"},"modified":"2022-11-14T20:52:05","modified_gmt":"2022-11-14T18:52:05","slug":"scope","status":"publish","type":"page","link":"https:\/\/www.oramanetwork.gr\/en\/?page_id=10","title":{"rendered":"Scope"},"content":{"rendered":"<hr \/>\n<p><strong>The aim of the project, <\/strong>following a specific strategy of rational and scientifically substantiated approach, is to develop an innovative molecule for the targeted treatment of hormone-dependent cancer. The product will comprise a peptide analogue of GnRH (Gonadotropin Releasing Hormone \u03ae LHRH, Luteinizing Hormone-Releasing Hormone) conjugated with a cytostatic agent for the selective destruction of GnRH receptor-bearing cancer cells. The goal is to reduce the side effects of chemotherapy and achieve better efficacy.<\/p>\n<p><strong>Additional objectives of the project are:<\/strong><\/p>\n<ul>\n<li><span style=\"color: #b20101;\"><strong>i) <\/strong><\/span>The connection of research and innovation with entrepreneurship;<\/li>\n<li><span style=\"color: #b20101;\"><strong>(ii)<\/strong><\/span> The emergence and confirmation of a new and innovative, targeted cancer treatment;<\/li>\n<li><span style=\"color: #b20101;\"><strong>(iii)<\/strong> <\/span>The acquisition of new knowledge and skills that will be created by the collaboration of Excelya (formerly ZeinCRO) with research organizations, with the prospect of creating an improved anti-cancer molecule and promoting it in the &#8220;drug market&#8221; and<\/li>\n<li><span style=\"color: #b20101;\"><strong>(iv)<\/strong> <\/span>Creating a business plan from the company (Excelya, formerly ZeinCRO) for product development .<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>The aim of the project, following a specific strategy of rational and scientifically substantiated approach, is to develop an innovative molecule for the targeted treatment of hormone-dependent cancer. The product will comprise a peptide analogue of GnRH (Gonadotropin Releasing Hormone \u03ae LHRH, Luteinizing Hormone-Releasing Hormone) conjugated with a cytostatic agent for the selective destruction of &#8230; <a title=\"Scope\" class=\"read-more\" href=\"https:\/\/www.oramanetwork.gr\/en\/?page_id=10\" aria-label=\"Read more about Scope\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-10","page","type-page","status-publish"],"_links":{"self":[{"href":"https:\/\/www.oramanetwork.gr\/en\/index.php?rest_route=\/wp\/v2\/pages\/10","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.oramanetwork.gr\/en\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.oramanetwork.gr\/en\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.oramanetwork.gr\/en\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.oramanetwork.gr\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10"}],"version-history":[{"count":5,"href":"https:\/\/www.oramanetwork.gr\/en\/index.php?rest_route=\/wp\/v2\/pages\/10\/revisions"}],"predecessor-version":[{"id":280,"href":"https:\/\/www.oramanetwork.gr\/en\/index.php?rest_route=\/wp\/v2\/pages\/10\/revisions\/280"}],"wp:attachment":[{"href":"https:\/\/www.oramanetwork.gr\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}